Active

ASTERION RESEARCH & DEVELOPMENT

Switched

BE0682704608

Rechtspersoon Private limited company 1 establishment

Karel van de Woestijnestraat 6, 9000 Gent Speur- en ontwikkelingswerk op biotechnologisch gebied

Active for

8 year, 11 months

Financials

Financial year 2025

Worth noting

  • Little cash and receivables against the short-term debts.

Gross margin

€ -91,977

▼ 177% vs 2024

Profit

Caution

€ -621,245

▼ 1772% vs 2024

Debts

Low

€ 662,480

▲ 13% vs 2024

ASTERION RESEARCH & DEVELOPMENT from Gent, company number BE0682704608, closed financial year 2025 with a result of € -621,245 after tax. For that financial year ASTERION RESEARCH & DEVELOPMENT recorded a gross margin of € -91,977 and equity of € 1.6 million. Compared with financial year 2024, the result moved from € 37,163 to € -621,245. The company made a loss. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.

What happened at ASTERION RESEARCH & DEVELOPMENT?

What happened at ASTERION RESEARCH & DEVELOPMENT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • New annual accounts for financial year 2025: loss of € 621,245 (▼ 1772% vs 2024). Source: NBB ↗
  • New establishment in Gent. KBO
  • Jeroen Hofenk became a director. NBB
  • Start of the company according to the CBE. KBO

In short

From € 32,228 profit in 2021 to € 621,245 loss in 2025.

Best year ever: 2022, with € 249,794 profit.

A new publication or filing at ASTERION RESEARCH & DEVELOPMENT? We notify you, reason included.

Follow ASTERION RESEARCH & DEVELOPMENT

Need more data?

History

Every financial year, as far back as the National Bank goes.

Buffer

How long does the company survive without income?

Credit limit

Indicative credit limit, computed from the real figures.

Alerts

New annual account: profit halved. New
Gazette: capital increase of 250k. New

News about who you follow, reason included.

Databakkes Pro · first month free

Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.

Management

Jeroen Hofenk
ASTERION RESEARCH & DEVELOPMENT
Bombi Biomics 30%

Behind ASTERION RESEARCH & DEVELOPMENT is Jeroen Hofenk. It owns 52.8% of Swiftpharma and 30% of Bombi Biomics itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Jeroen Hofenk

Director

Also active at: Swiftpharma, HofMan

since 2017

Establishments

Establishment units

Physical locations of this company

Registered office

Karel van de Woestijnestraat 6

9000 Gent

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

Details

Company number
0682.704.608
VAT number
BE 0682.704.608
Registered office
Karel van de Woestijnestraat 6, 9000 Gent
Names & denominations
ASTERION RESEARCH & DEVELOPMENT
Enterprise type
Rechtspersoon
Legal form
Private limited company
Legal situation
Normale toestand
Start date
9 October 2017
Peppol
Active · Active since 20 May 2025
Activities · NACE

Speur- en ontwikkelingswerk op biotechnologisch gebied

Vervaardiging van farmaceutische grondstoffen

Frequently asked questions

What is the enterprise number of ASTERION RESEARCH & DEVELOPMENT?
The enterprise number of ASTERION RESEARCH & DEVELOPMENT is BE0682704608.
What is the address of ASTERION RESEARCH & DEVELOPMENT?
The registered office of ASTERION RESEARCH & DEVELOPMENT is located at Karel van de Woestijnestraat 6, 9000 Gent.
When was ASTERION RESEARCH & DEVELOPMENT founded?
ASTERION RESEARCH & DEVELOPMENT was founded on 9 October 2017.
What is the main activity of ASTERION RESEARCH & DEVELOPMENT?
The main activity of ASTERION RESEARCH & DEVELOPMENT is "Speur- en ontwikkelingswerk op biotechnologisch gebied" (NACE code 72101).
Does ASTERION RESEARCH & DEVELOPMENT have a website?
No website is currently known for ASTERION RESEARCH & DEVELOPMENT.
How much profit did ASTERION RESEARCH & DEVELOPMENT make in 2025?
ASTERION RESEARCH & DEVELOPMENT recorded a loss after taxes of € 621,245 in financial year 2025.
What is the revenue of ASTERION RESEARCH & DEVELOPMENT?
As a small company, ASTERION RESEARCH & DEVELOPMENT is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -91,977.
Where can I find the annual accounts of ASTERION RESEARCH & DEVELOPMENT?
ASTERION RESEARCH & DEVELOPMENT files its annual accounts with the Central Balance Sheet Office of the National Bank of Belgium. The key figures for recent financial years are available for free on this page.
Who are the directors of ASTERION RESEARCH & DEVELOPMENT?
According to the 2025 annual accounts, the directors of ASTERION RESEARCH & DEVELOPMENT are: Jeroen Hofenk.
Who owns ASTERION RESEARCH & DEVELOPMENT?
Behind ASTERION RESEARCH & DEVELOPMENT is Jeroen Hofenk. It owns 52.8% of Swiftpharma and 30% of Bombi Biomics itself.